United Therapeutics (NASDAQ:UTHR) Downgraded to “Buy” at StockNews.com

StockNews.com downgraded shares of United Therapeutics (NASDAQ:UTHRFree Report) from a strong-buy rating to a buy rating in a report issued on Tuesday.

UTHR has been the topic of several other reports. Oppenheimer upped their price objective on United Therapeutics from $375.00 to $400.00 and gave the stock an outperform rating in a report on Thursday, May 2nd. The Goldman Sachs Group upped their price objective on United Therapeutics from $218.00 to $240.00 and gave the stock a neutral rating in a report on Friday, May 3rd. SVB Leerink began coverage on United Therapeutics in a research report on Monday, February 5th. They set an outperform rating and a $330.00 target price on the stock. Wedbush reissued an outperform rating and set a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. boosted their target price on United Therapeutics from $280.00 to $300.00 and gave the company an overweight rating in a research report on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $309.44.

View Our Latest Stock Report on United Therapeutics

United Therapeutics Stock Down 0.1 %

NASDAQ UTHR opened at $276.40 on Tuesday. The stock’s 50 day moving average is $253.45 and its 200 day moving average is $236.90. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $280.00. The stock has a market cap of $12.26 billion, a PE ratio of 13.07, a P/E/G ratio of 4.07 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHRGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. During the same period in the previous year, the firm earned $4.86 EPS. The firm’s revenue was up 33.7% compared to the same quarter last year. Research analysts predict that United Therapeutics will post 24.61 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,756.70. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,756.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $236.45, for a total value of $1,418,700.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $8,680,079.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 164,328 shares of company stock valued at $40,002,673. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of United Therapeutics

Several large investors have recently made changes to their positions in UTHR. Cetera Advisors LLC purchased a new stake in United Therapeutics in the first quarter valued at $475,000. Burney Co. boosted its holdings in United Therapeutics by 119.1% in the first quarter. Burney Co. now owns 22,449 shares of the biotechnology company’s stock valued at $5,157,000 after purchasing an additional 12,205 shares during the last quarter. Beck Bode LLC purchased a new stake in United Therapeutics in the first quarter valued at $1,839,000. Swedbank AB purchased a new stake in United Therapeutics in the first quarter valued at $97,316,000. Finally, Delphi Management Inc. MA purchased a new stake in United Therapeutics in the first quarter valued at $1,357,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.